Synonym
Clorazepate monopotassium; Abbott-39083; Abbott 39083; Abbott39083
IUPAC/Chemical Name
1H-1,4-Benzodiazepine-3-carboxylic acid, 2,3-dihydro-7-chloro-2-oxo-5-phenyl-, monopotassium salt
InChi Key
ULEUKTXFAJZAAV-UHFFFAOYSA-M
InChi Code
InChI=1S/C16H11ClN2O3.K/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12;/h1-8,14H,(H,18,20)(H,21,22);/q;+1/p-1
SMILES Code
O=C(C1C(NC2=CC=C(Cl)C=C2C(C3=CC=CC=C3)=N1)=O)[O-].[K+]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
352.82
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Clorazepate. 2018 Oct 31. PMID: 30000269.
2: Hanna S, Diana F, Slevinski J, Veronich K, Lachman L. Differential pulse polarographic determination of clorazepate monopotassium and dipotassium. J Pharm Sci. 1978 Dec;67(12):1723-5. doi: 10.1002/jps.2600671224. PMID: 31451.
3: Cohn JB, Bowden CL, Fisher JG, Rodos JJ. Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med. 1986 Mar 31;80(3B):10-6. doi: 10.1016/0002-9343(86)90326-8. PMID: 2870640.
4: Fujii T, Okuno T, Go T, Ochi J, Hattori H, Kataoka K, Mikawa H. Clorazepate therapy for intractable epilepsy. Brain Dev. 1987;9(3):288-91. doi: 10.1016/s0387-7604(87)80046-3. PMID: 2889387.
5: Elrod L Jr, Shada DM, Taylor VE. High-performance liquid chromatographic analysis of clorazepate dipotassium and monopotassium in solid dosage forms. J Pharm Sci. 1981 Jul;70(7):793-5. doi: 10.1002/jps.2600700721. PMID: 6115049.
6: Forrester SD, Brown SA, Lees GE, Hartsfield SM. Disposition of clorazepate in dogs after single- and multiple-dose oral administration. Am J Vet Res. 1990 Dec;51(12):2001-5. PMID: 2085227.
7: Bartenbach DE. Clorazepate dipotassium. Am Fam Physician. 1978 Oct;18(4):43,46,50. PMID: 30272.
8: Mimaki T, Tagawa T, Ono J, Tanaka J, Terada H, Itoh N, Yabuuchi H. Antiepileptic effect and serum levels of clorazepate on children with refractory seizures. Brain Dev. 1984;6(6):539-44. doi: 10.1016/s0387-7604(84)80097-2. PMID: 6152517.
9: Suzuki EM, Gresham WR. Identification of some interferences in the analysis of clorazepate. J Forensic Sci. 1983 Jul;28(3):655-82. PMID: 6137507.
10: Livingston S, Pauli LL. Clorazepate in epilepsy. JAMA. 1977 Apr 11;237(15):1561. PMID: 15140.
